| Scott E Rojas, MD | |
|
1326 Eisenhower Dr, Bldg 2, Savannah, GA 31406-3928 | |
| (912) 354-5543 | |
| (912) 354-9365 |
| Full Name | Scott E Rojas |
|---|---|
| Gender | Male |
| Speciality | Infectious Disease |
| Experience | 30 Years |
| Location | 1326 Eisenhower Dr, Savannah, Georgia |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1285609784 | NPI | - | NPPES |
| P00202555 | Other | MEDICARE RAILROAD | |
| 8J8301 | Other | TX | BCBS |
| 151155202 | Medicaid | TX |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207RI0200X | Internal Medicine - Infectious Disease | L3801 (Texas) | Secondary |
| 207RI0200X | Internal Medicine - Infectious Disease | 076675 (Georgia) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Memorial University Medical Center | Savannah, GA | Hospital |
| St Joseph's Hospital - Savannah | Savannah, GA | Hospital |
| Candler Hospital | Savannah, GA | Hospital |
| Candler County Hospital | Metter, GA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Privia Medical Group Of Georgia Llc | 4284951542 | 301 |
News Archive
Targacept, Inc today announced top-line results from a Phase 2 proof of concept trial of TC-5619 as a treatment for adults with attention deficit/hyperactivity disorder.
A first-of-its-kind stem cell-based treatment for retinitis pigmentosa developed by UC Irvine's Dr. Henry Klassen, Dr. Jing Yang and colleagues has received consent from the U.S. Food & Drug Administration for use in a clinical trial.
Contending that President Barack Obama and U.S. Congressman Joe Wilson were both right and both wrong in their much noted confrontation during the President's address to Congress on Wednesday, the Foundation for Health Coverage Education (FHCE), www.coverageforall.org, points out that the issue is with the definition of health coverage versus health care for undocumented immigrants in HR3200, the House's version of healthcare reform legislation.
Amira Pharmaceuticals, Inc. announced today that it will present preclinical and clinical data from its DP2 receptor antagonist program on December 17, 2010, at Pacifichem 2010 in Honolulu, Hawaii. The data from Amira's clinical-stage DP2 program will be delivered by Brian Stearns, Ph.D., in a presentation titled "Discovery and optimization of a novel series of DP2 antagonists with efficacy in mouse models of COPD and asthma."
› Verified 8 days ago
| Entity Name | Southcoast Medical Group Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467451922 PECOS PAC ID: 9032013271 Enrollment ID: O20040109000192 |
News Archive
Targacept, Inc today announced top-line results from a Phase 2 proof of concept trial of TC-5619 as a treatment for adults with attention deficit/hyperactivity disorder.
A first-of-its-kind stem cell-based treatment for retinitis pigmentosa developed by UC Irvine's Dr. Henry Klassen, Dr. Jing Yang and colleagues has received consent from the U.S. Food & Drug Administration for use in a clinical trial.
Contending that President Barack Obama and U.S. Congressman Joe Wilson were both right and both wrong in their much noted confrontation during the President's address to Congress on Wednesday, the Foundation for Health Coverage Education (FHCE), www.coverageforall.org, points out that the issue is with the definition of health coverage versus health care for undocumented immigrants in HR3200, the House's version of healthcare reform legislation.
Amira Pharmaceuticals, Inc. announced today that it will present preclinical and clinical data from its DP2 receptor antagonist program on December 17, 2010, at Pacifichem 2010 in Honolulu, Hawaii. The data from Amira's clinical-stage DP2 program will be delivered by Brian Stearns, Ph.D., in a presentation titled "Discovery and optimization of a novel series of DP2 antagonists with efficacy in mouse models of COPD and asthma."
› Verified 8 days ago
| Entity Name | Privia Medical Group Of Georgia Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1013313857 PECOS PAC ID: 4284951542 Enrollment ID: O20150325000983 |
News Archive
Targacept, Inc today announced top-line results from a Phase 2 proof of concept trial of TC-5619 as a treatment for adults with attention deficit/hyperactivity disorder.
A first-of-its-kind stem cell-based treatment for retinitis pigmentosa developed by UC Irvine's Dr. Henry Klassen, Dr. Jing Yang and colleagues has received consent from the U.S. Food & Drug Administration for use in a clinical trial.
Contending that President Barack Obama and U.S. Congressman Joe Wilson were both right and both wrong in their much noted confrontation during the President's address to Congress on Wednesday, the Foundation for Health Coverage Education (FHCE), www.coverageforall.org, points out that the issue is with the definition of health coverage versus health care for undocumented immigrants in HR3200, the House's version of healthcare reform legislation.
Amira Pharmaceuticals, Inc. announced today that it will present preclinical and clinical data from its DP2 receptor antagonist program on December 17, 2010, at Pacifichem 2010 in Honolulu, Hawaii. The data from Amira's clinical-stage DP2 program will be delivered by Brian Stearns, Ph.D., in a presentation titled "Discovery and optimization of a novel series of DP2 antagonists with efficacy in mouse models of COPD and asthma."
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Scott E Rojas, MD Po Box 15849, Savannah, GA 31416-2549 Ph: (912) 303-3560 | Scott E Rojas, MD 1326 Eisenhower Dr, Bldg 2, Savannah, GA 31406-3928 Ph: (912) 354-5543 |
News Archive
Targacept, Inc today announced top-line results from a Phase 2 proof of concept trial of TC-5619 as a treatment for adults with attention deficit/hyperactivity disorder.
A first-of-its-kind stem cell-based treatment for retinitis pigmentosa developed by UC Irvine's Dr. Henry Klassen, Dr. Jing Yang and colleagues has received consent from the U.S. Food & Drug Administration for use in a clinical trial.
Contending that President Barack Obama and U.S. Congressman Joe Wilson were both right and both wrong in their much noted confrontation during the President's address to Congress on Wednesday, the Foundation for Health Coverage Education (FHCE), www.coverageforall.org, points out that the issue is with the definition of health coverage versus health care for undocumented immigrants in HR3200, the House's version of healthcare reform legislation.
Amira Pharmaceuticals, Inc. announced today that it will present preclinical and clinical data from its DP2 receptor antagonist program on December 17, 2010, at Pacifichem 2010 in Honolulu, Hawaii. The data from Amira's clinical-stage DP2 program will be delivered by Brian Stearns, Ph.D., in a presentation titled "Discovery and optimization of a novel series of DP2 antagonists with efficacy in mouse models of COPD and asthma."
› Verified 8 days ago
Florin C Georgescu, M. D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 500 E 66th St, Savannah, GA 31405 Phone: 912-356-5643 Fax: 912-356-9712 | |
James A Daly Iii, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 340 Hodgson Ct, Suite 2, Savannah, GA 31406 Phone: 912-629-2290 Fax: 912-629-2291 | |
Elizabeth Florence Cornell, DO Infectious Disease Medicare: May Accept Medicare Assignments Practice Location: 6602 Waters Ave Bldg A, Savannah, GA 31406 Phone: 912-350-6000 Fax: 912-350-6001 | |
Dr. Kinhtu Lien, MD Infectious Disease Medicare: Not Enrolled in Medicare Practice Location: 4700 Waters Ave, Savannah, GA 31404 Phone: 912-350-7573 | |
Dr. Barry James Krakow, MD Infectious Disease Medicare: Not Enrolled in Medicare Practice Location: 211 Early St, Savannah, GA 31405 Phone: 505-238-7519 | |
Dr. John David Northup, M.D. Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 12345 Mercy Blvd, Savannah, GA 31419 Phone: 912-927-3046 Fax: 912-925-0597 | |
Samuel David Patrick Mcelroy, MD Infectious Disease Medicare: Accepting Medicare Assignments Practice Location: 4451 Paulsen St, Savannah, Savannah, GA 31405 Phone: 912-350-7500 Fax: 912-350-7735 |